abstract |
The present invention relates to human antibodies that recognize human C5a receptors. These antibodies inhibit C5a signaling by binding to C5aR, thereby inhibiting pro-inflammatory signaling. Based on the role of C5a and its receptors in stimulating inflammation, the invention further relates to the therapeutic use of such human anti-C5aR antibodies, particularly with regard to the therapeutic use of immunological disorders. |